BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genomatix Closes Series B Financing Round


10/19/2005 5:10:02 PM

ROANOKE, Va.--(BUSINESS WIRE)--May 17, 2005--Genomatix Corporation today announced that it has closed its Series B round of financing involving a $500,000 investment by NewVa Capital Partners, LP, a venture capital fund managed by Third Security, LLC of Radford, Va. Genomatix provides tools for controlling gene expression and modulating protein interactions. By turning genes "on" and "off" to regulate the production of proteins, scientists can study cell behavior in more detailed and complex ways than ever before. Thomas Reed, Ph.D., Chairman and Chief Science Officer of Genomatix states, "These tools can help point the way to promising therapeutic candidates while helping to avoid potentially harmful side effects." Genomatix will use the proceeds of the financing to accelerate the roll out and marketing of its proprietary genetic tools. "The completion of this investment round is a significant milestone for us. Third Security is a highly regarded life science investor. The fund's commitment to Genomatix is a strong indicator that we are on the right track both scientifically and commercially. We believe that this investment positions us for substantial growth," said Robert Beech, CEO of Genomatix.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES